AR100820A1 - Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas - Google Patents
Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismasInfo
- Publication number
- AR100820A1 AR100820A1 ARP150101871A ARP150101871A AR100820A1 AR 100820 A1 AR100820 A1 AR 100820A1 AR P150101871 A ARP150101871 A AR P150101871A AR P150101871 A ARP150101871 A AR P150101871A AR 100820 A1 AR100820 A1 AR 100820A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- layer
- capecitabine
- cyclofosphamide
- fractioned
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación de comprimido oral bi-capa de ciclofosfamida y capecitabina y métodos de preparación de estas formulaciones. Además, dichas formulaciones son útiles para administración metronómica para tratar cáncer, por ejemplo, cáncer de mama. Reivindicación 4: La formulación de comprimido de una cualquiera de las reivindicaciones 1 a 3, en la que el único comprimido bi-capa está recubierto con película. Reivindicación 7: La formulación de comprimido de la reivindicación 6, en la que el recubrimiento con película aplicado comprende la composición siguiente: @@@@@@@@@
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1596DE2014 | 2014-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100820A1 true AR100820A1 (es) | 2016-11-02 |
Family
ID=53724388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101871A AR100820A1 (es) | 2014-06-12 | 2015-06-11 | Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR100820A1 (es) |
TW (1) | TW201613563A (es) |
WO (1) | WO2015189807A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201809658UA (en) * | 2016-05-03 | 2018-11-29 | Intas Pharmaceuticals Ltd | Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009539769A (ja) * | 2006-06-02 | 2009-11-19 | アリアド ジーン セラピューティクス インコーポレイテッド | カペシタビン併用療法 |
EP2747571A4 (en) * | 2011-08-24 | 2015-05-27 | David Kerr | COMBINED COMBINED CHEMOTHERAPY |
EP3052130B1 (en) * | 2013-09-30 | 2019-08-07 | Intas Pharmaceuticals Limited | Pharmaceutical composition comprising capecitabine and cyclophosphamide |
-
2015
- 2015-06-11 AR ARP150101871A patent/AR100820A1/es unknown
- 2015-06-11 TW TW104118984A patent/TW201613563A/zh unknown
- 2015-06-12 WO PCT/IB2015/054447 patent/WO2015189807A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201613563A (en) | 2016-04-16 |
WO2015189807A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
CO2018008207A2 (es) | Composiciones para el cuidado bucal y métodos para utilizar las composiciones | |
MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
PH12019501970A1 (en) | Pharmaceutical compositions for combination therapy | |
CL2018001686A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026) | |
CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
CL2020001226A1 (es) | Proceso para preparar tapinarof. | |
CO2019008103A2 (es) | Composiciones farmacéuticas para terapia de combinación | |
CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CL2018001590A1 (es) | Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida | |
PH12016502386B1 (en) | Oral care compositions | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
MX2018014790A (es) | Formulacion combinada de tres compuestos antivirales. | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
AR100820A1 (es) | Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |